Trexquant Investment LP Sells 38,402 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Trexquant Investment LP decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 28.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,577 shares of the specialty pharmaceutical company’s stock after selling 38,402 shares during the period. Trexquant Investment LP owned approximately 0.29% of Collegium Pharmaceutical worth $2,911,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of COLL. Principal Securities Inc. bought a new position in Collegium Pharmaceutical in the 4th quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after acquiring an additional 2,877 shares during the period. Versor Investments LP acquired a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth about $207,000. O Shaughnessy Asset Management LLC boosted its stake in shares of Collegium Pharmaceutical by 14.3% in the third quarter. O Shaughnessy Asset Management LLC now owns 11,509 shares of the specialty pharmaceutical company’s stock valued at $257,000 after buying an additional 1,440 shares in the last quarter. Finally, Johnson Investment Counsel Inc. acquired a new position in Collegium Pharmaceutical in the fourth quarter valued at $257,000.

Collegium Pharmaceutical Trading Up 1.3 %

Collegium Pharmaceutical stock traded up $0.43 during mid-day trading on Friday, hitting $34.25. 320,990 shares of the company’s stock were exchanged, compared to its average volume of 506,732. The company’s 50 day simple moving average is $36.74 and its 200-day simple moving average is $33.11. The firm has a market capitalization of $1.12 billion, a P/E ratio of 14.27 and a beta of 1.06. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now directly owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 3.98% of the company’s stock.

Analysts Set New Price Targets

COLL has been the subject of a number of research analyst reports. Truist Financial lifted their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Piper Sandler lowered shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price on the stock. in a report on Friday, May 10th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Needham & Company LLC lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $39.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.